This would require quantitatively differentiating the fraction of the dose that was not absorbed from the fraction of the dose that was absorbed and excreted unchanged directly into the intestinal tract, i.e. knowing the absolute bioavailability of apixaban in these subjects. Because apixaban is an ...
(NOACs) with warfarin for thromboprophylaxis in patients with AF, the efficacy and safety of NOACs in patients with mild-to-moderate CKD were similar to those in patients without CKD. Dose adjustment of NOACs as per the prescribing label is required in this population. Owing to limited trial...